Zevra Therapeutics, Inc. ZVRA 深 沪
交易中 03-27 10:26:41 美东时间
9.34
-0.060
-0.64%
华盛通- 最 高11.40
- 今 开9.33
- 成交量 7.73万股
- 最 低 8.42
- 昨 收 9.40
- 总市值 0
- 52周最高 13.16
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 6.19
- 委 比 14.18%
- 总股本 --
- 历史最高 13.16
- 量 比 1.27
- 振 幅 31.70%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多US Stocks Mixed; United Natural Foods Shares Fall After Q2 Results
US stocks mixed, Dow down 0.1%, NASDAQ up 0.13%, S&P 500 down 0.08%. Materials sector up, utilities down. United Natural Foods stock falls 7%.
03-10 22:40
Zevra Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
Zevra Therapeutics shares are trading higher after the company reported better-...
03-10 04:14
Earnings Scheduled For March 9, 2026
Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is exp...
03-09 19:11
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
2025-11-03 22:14
Zevra治疗公司营收增长26%
罕见病药物开发商Zevra治疗公司（ZVRA）报告营收增长26%并完成1.5亿美元优先审评券（PRV）出售，显著增强了资产负债表实力。该公司正着力扩大市场覆盖范围并为持续进行的临床试验提供支持。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-08-13 22:36
Zevra Therapeutics FY 2024 GAAP EPS $(2.28) Misses $(1.99) Estimate, Sales $23.600M Beat $20.514M Estimate
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.99) by 14.57 percent. The company reported quarterly sales of $23.600 million which beat
2025-03-12 04:13
Earnings Scheduled For March 11, 2025
Companies Reporting Before The Bell • Exagen (NASDAQ:XGN) is projected to repor...
2025-03-11 16:32
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
7 analysts have expressed a variety of opinions on Zevra Therapeutics (NASDAQ:Z...
2024-09-25 01:01
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic Metabolic Diseases Advisory Committee.
2024-09-21 01:27
